tiprankstipranks

Alimera Sciences downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen downgraded Alimera Sciences (ALIM) to Neutral from Buy with an unchanged price target of $6 after the company entered into a definitive agreement under which ANI Pharmaceuticals (ANI) would acquire Alimera for $5.50 per share in cash plus a non-tradable contingent value right of up to 50c per share upon the achievement of certain net revenue targets in 2026 and 2027.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue